Invites Biocore Co., Ltd.

A216400

KR7216400002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 20/05/2024 BST			5-day change	1st Jan Change
8,750 ^KRW	+0.34%		-7.31%	-5.91%

2023	CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	CI
2023	Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	CI

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion

December 27, 2023

CrystalGenomics Invites Co., LTD. (KOSDAQ:A083790) agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. (XKON:A216400) and others for KRW 13.1 billion on December 28, 2023.

Latest news about Invites Biocore Co., Ltd.

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion	12-27	CI
Invites Healthcare Co., Ltd. agreed to acquire Invites Genomics Co., Ltd. from Invites Biocore Co., Ltd. for KRW 10 billion	16/05/23	CI
Invites Biocore Co., Ltd. completed the acquisition of 85% stake in PROCAGEN from Byun Seok-soo.	14/07/22	CI
Invites Biocore Co., Ltd. agreed to acquire 85% stake in PROCAGEN from Byun Seok-soo.	13/07/22	CI
Biocore Co., Ltd. announced that it has received KRW 41.999997 billion in funding	30/03/21	CI
Biocore Co., Ltd. announced that it expects to receive KRW 41.999997 billion in funding	16/02/21	CI
BioCore Inc. Signs Agreement with Osprey Medical, Inc	25/11/20	CI
Biocore Co., Ltd. announced that it has received KRW 7.99999527 billion in funding	07/07/20	CI
Invites Healthcare Co., Ltd. agreed to acquire a 20.03% stake in Biocore Co., Ltd. from Hongkong Dian Biotechnology Co., Limited for KRW 12 billion.	30/06/20	CI
Biocore Co., Ltd. announced that it expects to receive KRW 7.99999527 billion in funding	29/06/20	CI
Biocore Co., Ltd. announced that it expects to receive KRW 5.04114275 billion in funding	30/09/19	CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1, MAVI New Growth Good Corporation Investment Fund No. 2 acquired 2.67% stake in Biocore Co., Ltd. from Kwanghyun Lee and Seunghyun Lee for KRW 2.1 billion.	02/08/16	CI
Kiwoom Securities Co., Ltd. acquired approximately 1.8% stake in Biocore Co., Ltd. from SCL Healthcare Co., Ltd. and Kyungryul Lee for approximately KRW 1.6 billion.	01/08/16	CI
IBKC-SBI Bio Fund 1 of SBI Investment Korea Co., Ltd., MAGNA Investment Co., Ltd., MGI Secondary Fund 1 of MG Investment Co., Ltd. and SEMA-InterVest Bio Healthcare Fund of InterVest Co., Ltd. acquired additional 5.56% stake in Biocore Co., Ltd. from Lee, Kyungryul for KRW 4.9 billion.	01/08/16	CI
SBI Investment Korea Co., Ltd. through its SBI-Growth Ladder KONEX Vitalization Fund acquired 2.3% stake in Biocore Co., Ltd. from Kyungryul Lee for KRW 1.9 billion.	28/07/16	CI
Moon-Kyu Gong acquired 1.22% stake in Biocore Co., Ltd. from Jeong-Woo Lee for KRW 700 million.	27/10/15	CI
K2 Asset Securitization Specialty Investment Fund, Korea Omega Venture Investment No.1 Fund, MAVI New Growth Good Corporation Investment Fund No. 1 and MAVI New Growth Good Corporation Investment Fund No. 2 acquired 8.88% stake in Biocore Co., Ltd. from Kwang-Hyun Lee and Seung-Hyun Lee for KRW 4 billion.	27/10/15	CI
Biocore Co., Ltd. completed the acquisition of Cytogenetic and Human Genome division of Seoul Clinical Laboratories.	21/10/15	CI
Biocore Co., Ltd. agreed to acquire Cytogenetic and Human Genome division of Seoul Clinical Laboratories for KRW 2.9 billion.	18/08/15	CI
Intelsius Announces Partnership with Biocore Co. Ltd. in South Korea	27/03/12	CI

Chart Invites Biocore Co., Ltd.

Duration

Period

More charts

Invites Biocore Co Ltd, formerly BioCore Co Ltd, is a Korea-based company mainly engaged in the provision of medical examination services. The Company operates its business through two segments. The New Drug Development Business segment is involved in the provision of bioequivalence testing, drug in vivo kinetics research, drug analysis in biological samples, toxicity kinetics testing, microanalysis in pharmaceuticals, comparative dissolution testing, and clinical trial consulting. The Biotechnology Business segment is engaged in the provision of customized genome analysis services and the manufacture and sale of diagnostic kits. The Companyâs products are sold under the brand of Bio-Core.

Sector

Biotechnology & Medical Research

Calendar

23/05/2024 - Investor Meeting

More about the company

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
INVITES BIOCORE CO., LTD.	-5.91%	49.5M
EXACT SCIENCES CORPORATION	-27.66%	9.88B
IOVANCE BIOTHERAPEUTICS, INC.	+26.94%	2.89B
BGI GENOMICS CO., LTD.	-15.73%	2.12B
VERACYTE, INC.	-20.83%	1.67B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+67.18%	1.45B
CAREDX, INC	+26.08%	788M
SEEGENE, INC.	-4.15%	741M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-28.78%	514M
CURIOX BIOSYSTEMS CO., LTD	+3.98%	308M

Bio Diagnostics & Testing

Invites Biocore Co., Ltd.

Equities

A216400

KR7216400002

Biotechnology & Medical Research

CrystalGenomics Invites Co., LTD. agreed to acquire an 89.95% stake in PROCAGEN from Invites Biocore Co., Ltd. and others for KRW 13.1 billion

Latest news about Invites Biocore Co., Ltd.

Chart Invites Biocore Co., Ltd.

Company Profile

Sector Bio Diagnostics & Testing